Lexaria Bioscience’s LEXX powerful, proprietary drug delivery technology, DehydraTECH has the potential to disrupt multiple categories as the company continues to receive positive results from clinical testing.
DehydraTECH has clinically-demonstrated ability to improve the speed and concentration of active pharmaceutical ingredients in the bloodstream, increasing bio-absorption by up to 10x and reducing time of onset from hours to just minutes. Lexaria has spent the past three years successfully testing its technology across a variety of verticals, including pharmaceuticals and consumer goods.
The company has established itself as one of the world's leaders in the investigation of cannabidiol (CBD) for the purposes of controlling human blood pressure, and is now focused on launching an FDA-registered IND program to formally investigate DehydraTECH-CBD for hypertension this year.
We spoke to Lexaria’s Chief Executive Officer, Chris Bunka, to hear more about the company’s goals for 2023.
Q: Lexaria is making significant strides in evaluating DehydraTECH-CBD as a potential treatment for hypertension. What can investors expect to see next?
A: We are very excited about the progress we have made in our human clinical testing of DehydraTECH-CBD for hypertension. We have been able to demonstrate primary efficacy and safety and significant reductions in resting blood pressure in hypertensive patients and we are now progressing to initiating a Phase 1b study that will evaluate...
KEY POINTS Sam's Club may offer price matching if an item goes on sale. You'll need to take a photo or a screenshot of the sale price. You may be able to get a partial refund if the item has gone...
